Results 241 to 250 of about 4,287,179 (359)

In silico discovery of umami peptides: From sequence-based intelligent models to structure-function mechanistic insight. [PDF]

Curr Res Food Sci
Li X, Luo X, Xie S, Wei Y, Hong F, Jiang Y, Zhong X, Xie X, Ma C, Hao Y, Dao F, Yang K, Lin H, Lai H, Lyu H.   +14 more
europepmc   +1 more source

Cell Cycle Control of Nuclear Metabolism Couples Phosphatidylinositol Signaling to Histone Methylation

Advanced Science, EarlyView.
Nuclear metabolism oscillates during cell cycle progression. Quantitative chromatome proteomics and imaging reveal phase‐specific dynamics of PIP5K1A and nuclear PIP2, linking phosphatidylinositol metabolism to histone methylation. This work identifies nuclear lipid metabolism as a previously unrecognized regulatory axis coordinating chromatin ...
Antoni Gañez‐Zapater, Savvas Kourtis, Camilla Reiter Elbæk, Lorena Espinar, Carolina Toro‐Márquez, Albert Coll‐Manzano, Alfredo Smiriglia, Laura García‐López, Laura Wiegand, Maria Guirola, Frédéric Fontaine, Andrea Morandi, André C. Müller, Sara Sdelci   +13 more
wiley   +1 more source

Regulatory layers of robustness of CLAVATA-WUSCHEL feedback system in stem cell homeostasis. [PDF]

Front Plant Sci
Cerbantez-Bueno VE, Sheils PJ, Reddy GV.
europepmc   +1 more source

Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs‐STAT3 Pathway

Advanced Science, EarlyView.
Our study identifies the HDACs‐STAT3 axis as key regulator for M2 macrophage accumulation in DLBCL. We developed Chid@M2pep‐EVs/TP, a pH‐responsive drug delivery system for M2 macrophage specific chidamide administration. By coupling M2‐targeted chidamide with EVs‐mediated delivery, this system reprograms M2 to M1 via HDAC inhibition and STAT3 ...
Bo Dai, Shuo Wang, Xiaotong Peng, Kunpeng Wu, Mengyao Wu, Zhaoning Lu, Haoshu Zhong, Xiaohan Qian, Shuiyi Tan, Hui Yang, Tanlezi Sun, Jing Wang, Jie Zhang, Hua Jiang, Yin Tong, Tong Chen   +15 more
wiley   +1 more source

Opioid peptides in autism spectrum disorder and gluten-free casein-free diet as a therapeutic approach. [PDF]

Metab Brain Dis
Öztürk E, Aslan Çi̇n NN, Cansu A, Akyol A.   +3 more
europepmc   +1 more source

Pre‐Encoded IFN‐I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors

Advanced Science, EarlyView.
Type I interferon (IFN‐I) signaling promotes p21‐dependent cell cycle arrest in senescent tumor‐specific memory T cells, resulting in poor proliferative responses and solid tumor regression during cancer vaccination. Conversely, IFNα/β receptor blockade reinvigorates T cell proliferation to regress solid tumors and is more effective with increasing ...
Andrew Nguyen, Scott R Walsh, Li Deng, Lan Chen, Yonghong Wan   +4 more
wiley   +1 more source

Neuropeptides in the Management of Alzheimer's Disease: From Pathophysiology to Therapeutic Opportunities. [PDF]

Int J Mol Sci
Tiwari S, Yadav SK, Kumari M, Dhakal T, Puranik N.   +4 more
europepmc   +1 more source

ELABELA Targets Mitochondria to Modulate Heart Development

Advanced Science, EarlyView.
The role of peptide ELABELA (ELA) in cardiomyocyte apoptosis and congenital heart disease (CHD) is unclear. ELA deficiency caused cardiomyocyte apoptosis and CHD. A novel ELA‐APJ‐AKT‐BCL2/BAX axis in regulating mitochondrial function and contributing to CHD pathogenesis was established.
Jian Wang, Qingjie Wang, Zhikang Xu, Shuang Zhou, Yue Zhou, Junjie Yang, Lingfeng Tong, Zhuo Meng, Mei Yang, Wen Zhao, Tie Yang, Hualin Wang, Jun Zhang, Rubin Tan, Lei Wang, Yuqiang Huang, Bin Zhou, Sun Chen, Bing Zhang, Jinxiang Yuan, Jianyuan Zhao, Alex F. Chen, Kun Sun   +22 more
wiley   +1 more source

Cardioprotective mechanisms and effects of glucagon-like peptide-1 receptor agonists in autoimmune rheumatic diseases. [PDF]

Rheumatology (Oxford)
Karacabeyli D, Lacaille D.
europepmc   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source